Mitochondrial-Targeted Peptides (MTP)
Overview
Mitochondrial-targeted peptides are short synthetic sequences, typically 2 to 8 amino acids, designed to localize to mitochondria and protect against oxidative damage and organelle dysfunction. Representative compounds include SS-31 (elamipretide), a tetrapeptide that associates with cardiolipin in the inner mitochondrial membrane to reduce reactive oxygen species and improve electron transport chain efficiency. These peptides aim to address mitochondrial dysfunction implicated in aging, heart failure, neurodegenerative disease, and ischemia-reperfusion injury. The longevity application is based on the mitochondrial theory of aging and evidence that mitochondrial protection extends lifespan in model organisms.
Key Research Findings
Elamipretide advanced to phase 2 and 3 trials for primary mitochondrial myopathy (MMPOWER-3 trial) and heart failure, demonstrating mitochondrial functional improvements but missing primary efficacy endpoints in pivotal studies. A phase 2 trial in Barth syndrome showed statistically significant benefits on 6-minute walk distance. No clinical trials have specifically evaluated mitochondrial-targeted peptides for lifespan extension or general aging outcomes, with current evidence for longevity applications confined to preclinical models.
Subcutaneous injection, Intravenous
In Clinical Trials
Interested in Mitochondrial-Targeted Peptides (MTP)?
Find a verified provider experienced with Mitochondrial-Targeted Peptides (MTP) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Mitochondrial-Targeted Peptides (MTP) ProviderRelated Peptides
Epithalon (Epitalon)
Research PhaseA synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural epithalamin peptide produced by the pineal gland. Epithalon activates telomerase, the enzyme responsible for maintaining telomere length, thereby potentially extending cellular replicative capacity. It also stimulates melatonin production and modulates neuroendocrine system function associated with aging.
MOTS-c
Research PhaseA mitochondrial-derived peptide encoded by the 12S rRNA gene of mitochondrial DNA. MOTS-c is a 16-amino acid peptide that acts as an exercise mimetic by activating AMPK and regulating metabolic homeostasis. It translocates to the nucleus under metabolic stress to regulate nuclear gene expression related to glucose metabolism and cellular stress responses.
Humanin
Research PhaseA 24-amino acid mitochondrial-derived peptide encoded within the 16S rRNA region of mitochondrial DNA. Humanin exerts cytoprotective and neuroprotective effects by interacting with IGFBP-3, BAX, and the FPRL-1 receptor. It inhibits apoptosis through suppression of the intrinsic mitochondrial death pathway and reduces amyloid-beta-induced neurotoxicity.
NAD+ Precursors (NMN)
In Clinical TrialsNicotinamide mononucleotide (NMN) is a direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for cellular metabolism, DNA repair (via sirtuins and PARPs), and circadian rhythm regulation. NAD+ levels decline with age, and NMN supplementation restores tissue NAD+ levels, activating SIRT1-mediated pathways that regulate mitochondrial biogenesis and oxidative stress resistance.